Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Editas Medicine Inc (NASDAQ: EDIT) closed at $2.33 down -0.43% from its previous closing price of $2.34. In other words, the price has decreased by -$0.43 from its previous closing price. On the day, 1.51 million shares were traded. EDIT stock price reached its highest trading level at $2.439 during the session, while it also had its lowest trading level at $2.33.
Ratios:
For a deeper understanding of Editas Medicine Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 5.85 whereas as Long-Term Debt/Eq ratio is at 5.03.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 03 ’25 when Burkly Linda sold 713 shares for $2.15 per share. The transaction valued at 1,535 led to the insider holds 68,777 shares of the business.
O’Neill Gilmore Neil sold 5,603 shares of EDIT for $12,064 on Dec 03 ’25. The CEO now owns 269,087 shares after completing the transaction at $2.15 per share. On Dec 03 ’25, another insider, Parison Amy, who serves as the SVP, Chief Financial Officer of the company, sold 461 shares for $2.15 each. As a result, the insider received 993 and left with 15,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 227451456 and an Enterprise Value of 81455480. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.90 while its Price-to-Book (P/B) ratio in mrq is 16.15. Its current Enterprise Value per Revenue stands at 1.756 whereas that against EBITDA is -0.727.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.15, which has changed by 0.93388426 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.54, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -17.36%, while the 200-Day Moving Average is calculated to be -1.67%.
Shares Statistics:
For the past three months, EDIT has traded an average of 2.47M shares per day and 1879450 over the past ten days. A total of 97.62M shares are outstanding, with a floating share count of 97.12M. Insiders hold about 0.51% of the company’s shares, while institutions hold 45.44% stake in the company. Shares short for EDIT as of 1764288000 were 10568381 with a Short Ratio of 4.28, compared to 1761868800 on 8665653. Therefore, it implies a Short% of Shares Outstanding of 10568381 and a Short% of Float of 10.850000399999999.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.63 and -$2.13 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.06, with 8.0 analysts recommending between -$0.62 and -$1.41.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $8.45M this quarter.It ranges from a high estimate of $40.5M to a low estimate of $500k. As of. The current estimate, Editas Medicine Inc’s year-ago sales were $30.6MFor the next quarter, 12 analysts are estimating revenue of $1.38M. There is a high estimate of $3.77M for the next quarter, whereas the lowest estimate is $500k.
A total of 13 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $56.28M, while the lowest revenue estimate was $16.3M, resulting in an average revenue estimate of $23.63M. In the same quarter a year ago, actual revenue was $32.31MBased on 13 analysts’ estimates, the company’s revenue will be $16.65M in the next fiscal year. The high estimate is $41M and the low estimate is $2M.
